Our Families Can't Afford Cuts to NIH Funding

The National Institutes of Health (NIH), in particular its National Cancer Institute (NCI), is the largest source of funding for pediatric brain tumor research worldwide. These agencies play a central role in advancing our understanding of pediatric brain tumors, enhancing clinical care, and delivering hope through innovation. NIH/NCI also provides essential access to clinical trials and expert second opinions that families rely on in their search for better treatment options.

Research supported by the NIH has been behind nearly every major advance in pediatric brain tumor treatment—from basic science discoveries to clinical breakthroughs. Continued investment in this research is critical for developing safer, more effective therapies for the deadliest childhood cancer, as well as reducing long-term side effects for survivors.

The President’s FY2026 budget proposal would cut NIH funding by over 40%, NCI funding by over 37%, and consolidate 27 NIH institutes into just eight. While efficiencies are important, these extreme cuts would severely destabilize the landscape of pediatric brain tumor research. Steep cuts could also threaten to halt critical clinical trials, stall scientific progress, and limit patient access to promising new therapies. Investments in U.S.-based research funding are investments in the economy, which currently sees $2.56 in economic activity for every $1 invested in NIH research.

As they debate next year’s fiscal budget, the Pediatric Brain Tumor Foundation urges Congress to maintain its strong bipartisan support for NIH funding, ensuring that pediatric brain tumor research can continue moving forward. Increased investment will drive the development of new treatment options, attract and retain scientific talent in the field, and support the infrastructure needed to carry out lifesaving work at institutions across the country.

For more information about how you can support federal research funding, visit our Advocacy Page.